Literature DB >> 21173233

Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.

Bernhard Kloo1, Daniel Nagel, Matthias Pfeifer, Michael Grau, Michael Düwel, Michelle Vincendeau, Bernd Dörken, Peter Lenz, Georg Lenz, Daniel Krappmann.   

Abstract

The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) represents a very aggressive human lymphoma entity. Constitutive NF-κB activation caused by chronic active B-cell receptor (BCR) signaling is common feature of many ABC DLBCL cells; however, the pathways linking BCR signaling to the NF-κB prosurvival network are largely unknown. Here we report that constitutive activity of PI3K and the downstream kinase PDK1 are essential for the viability of two ABC DLBCL cell lines that carry mutations in the BCR proximal signaling adaptor CD79B. In these cells, PI3K inhibition reduces NF-κB activity and decreases the expression of NF-κB target genes. Furthermore, PI3K and PDK1 are required for maintaining MALT1 protease activity, which promotes survival of the affected ABC DLBCL cells. These results demonstrate a critical function of PI3K-PDK1 signaling upstream of MALT1 protease and NF-κB in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of PI3K inhibitors in DLBCL therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21173233      PMCID: PMC3017191          DOI: 10.1073/pnas.1008969108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

Review 2.  Src-family kinases in B-cell development and signaling.

Authors:  Stephen B Gauld; John C Cambier
Journal:  Oncogene       Date:  2004-10-18       Impact factor: 9.867

3.  High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Sverker Hasselblom; Ulrika Hansson; Markus Olsson; Leif Torén; Anders Bergström; Herman Nilsson-Ehle; Per-Ola Andersson
Journal:  Br J Haematol       Date:  2010-03-01       Impact factor: 6.998

4.  Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.

Authors:  Richard I Feldman; James M Wu; Mark A Polokoff; Monica J Kochanny; Harald Dinter; Daguang Zhu; Sandra L Biroc; Bruno Alicke; Judi Bryant; Shendong Yuan; Brad O Buckman; Dao Lentz; Mike Ferrer; Marc Whitlow; Marc Adler; Silke Finster; Zheng Chang; Damian O Arnaiz
Journal:  J Biol Chem       Date:  2005-03-16       Impact factor: 5.157

5.  Two-step cross-linking method for identification of NF-kappaB gene network by chromatin immunoprecipitation.

Authors:  David E Nowak; Bing Tian; Allan R Brasier
Journal:  Biotechniques       Date:  2005-11       Impact factor: 1.993

Review 6.  Mechanism of activation and function of protein kinase B.

Authors:  D R Alessi; P Cohen
Journal:  Curr Opin Genet Dev       Date:  1998-02       Impact factor: 5.578

7.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

Review 8.  The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer.

Authors:  Florian R Greten; Michael Karin
Journal:  Cancer Lett       Date:  2004-04-08       Impact factor: 8.679

9.  PI3K and Btk differentially regulate B cell antigen receptor-mediated signal transduction.

Authors:  Harumi Suzuki; Satoshi Matsuda; Yasuo Terauchi; Mari Fujiwara; Toshiaki Ohteki; Tomoichiro Asano; Timothy W Behrens; Taku Kouro; Kiyoshi Takatsu; Takashi Kadowaki; Shigeo Koyasu
Journal:  Nat Immunol       Date:  2003-02-03       Impact factor: 25.606

Review 10.  Phosphoinositide 3-kinase: diverse roles in immune cell activation.

Authors:  Jonathan A Deane; David A Fruman
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

View more
  57 in total

1.  PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases.

Authors:  Mathéa Pietri; Caroline Dakowski; Samia Hannaoui; Aurélie Alleaume-Butaux; Julia Hernandez-Rapp; Audrey Ragagnin; Sophie Mouillet-Richard; Stéphane Haik; Yannick Bailly; Jean-Michel Peyrin; Jean-Marie Launay; Odile Kellermann; Benoit Schneider
Journal:  Nat Med       Date:  2013-08-18       Impact factor: 53.440

Review 2.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

Review 3.  From MALT lymphoma to the CBM signalosome: three decades of discovery.

Authors:  Shaun Rosebeck; Aasia O Rehman; Peter C Lucas; Linda M McAllister-Lucas
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

4.  Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines.

Authors:  Stephan Hailfinger; Hendrik Nogai; Christiane Pelzer; Maike Jaworski; Katrin Cabalzar; Jean-Enno Charton; Montserrat Guzzardi; Chantal Décaillet; Michael Grau; Bernd Dörken; Peter Lenz; Georg Lenz; Margot Thome
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-22       Impact factor: 11.205

Review 5.  Malignant pirates of the immune system.

Authors:  Lixin Rui; Roland Schmitz; Michele Ceribelli; Louis M Staudt
Journal:  Nat Immunol       Date:  2011-09-20       Impact factor: 25.606

6.  Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking.

Authors:  Xingfeng Bao; Wanjun Zheng; Naoko Hata Sugi; Kishan L Agarwala; Qunli Xu; Zichun Wang; Karen Tendyke; Winnie Lee; Lana Parent; Wei Li; Hongsheng Cheng; Yongchun Shen; Noel Taylor; Zoltan Dezso; Hong Du; Yoshihiko Kotake; Nanding Zhao; John Wang; Maarten Postema; Mary Woodall-Jappe; Yasutaka Takase; Toshimitsu Uenaka; David G I Kingston; Kenichi Nomoto
Journal:  Cancer Biol Ther       Date:  2015-03-02       Impact factor: 4.742

Review 7.  Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.

Authors:  Ryan M Young; James D Phelan; Wyndham H Wilson; Louis M Staudt
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

Review 8.  NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

Authors:  Li Yu; Ling Li; L Jeffrey Medeiros; Ken H Young
Journal:  Blood Rev       Date:  2016-10-13       Impact factor: 8.250

Review 9.  Targeting the B-cell receptor signaling pathway in B lymphoid malignancies.

Authors:  Maike Buchner; Markus Müschen
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

10.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.

Authors:  Lesley A Mathews Griner; Rajarshi Guha; Paul Shinn; Ryan M Young; Jonathan M Keller; Dongbo Liu; Ian S Goldlust; Adam Yasgar; Crystal McKnight; Matthew B Boxer; Damien Y Duveau; Jian-Kang Jiang; Sam Michael; Tim Mierzwa; Wenwei Huang; Martin J Walsh; Bryan T Mott; Paresma Patel; William Leister; David J Maloney; Christopher A Leclair; Ganesha Rai; Ajit Jadhav; Brian D Peyser; Christopher P Austin; Scott E Martin; Anton Simeonov; Marc Ferrer; Louis M Staudt; Craig J Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.